Announcements Trials
Browse Landscape

Phase

Phase NA 4

Status

Unknown 4Completed 1

Sponsor Class

INDUSTRY 4OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Plasma cell 1Other hematologic neoplasm 1

Conditions

Plasmacytoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Hodgkin Disease 1

Interventions

Injections 54Cisplatin 49Paclitaxel 48Carboplatin 43Gemcitabine 38pembrolizumab 36Docetaxel 36Capecitabine 36Drug Therapy 34anlotinib 25Bevacizumab 25Fluorouracil 24Cyclophosphamide 24icotinib 23Oxaliplatin 20fludarabine 19Pemetrexed 17Leucovorin 16Irinotecan 16Temozolomide 14Nivolumab 14Doxorubicin 14Cetuximab 14camrelizumab 13apatinib 13Trastuzumab 12Rituximab 11Fulvestrant 11Etoposide 11tesetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Leukapheresis × Clear all
NCT04665063 2020-12-29

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
20 enrolled
Lymphoid

Hodgkin Disease

NCT04666168 2020-12-14

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
200 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT04665076 2020-12-11

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
60 enrolled
Plasma cell

Plasmacytoma

NCT04610125 2020-10-30

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡